Sun Pharmaceutical Industries Ltd. is the world’s fourth largest specialty generic pharmaceutical company. A vertically integrated business and a skilled team enables us to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Our global
presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D
centers, with investments of approximately 7% of annual revenues in R&D.

We are now poised to expand into Canada, establishing a Sun Pharma Canada Inc. affiliate in the coming months. Over the coming year, we will be launching two brands, tildrakizumab, an IL-23 for psoriasis and sonidegib, a new hedgehog inhibitor for basal cell carcinoma. Our goal is to demonstrate our commitment in Dermatology and working in close partnership with the Canadian Healthcare System and Patients.

Participant in Dermatology Update 2019 FALL Meeting:

Missing Event Data